Potential central nervous system antitumor agents. Hydantoin derivatives.
Hydantoin derivatives of varying lipophilic character were prepared as nitrogen mustard carriers for CNS antitumor evaluation. Activity was studied in the murine ependymoblastoma brain tumor system. Multiple cures were observed for three of the four analogs examined. The compounds were also active in the intraperitoneal leukemia L1210 and P388 systems as well as in B16 melanoma and Lewis lung carcinoma.
D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis*; D001932:Brain Neoplasms / Q000188:drug therapy; D002490:Central Nervous System; D004806:Ependymoma / Q000188:drug therapy; D006827:Hydantoins / Q000138:chemical synthesis* / Q000627:therapeutic use; D007770:L-Lactate Dehydrogenase / Q000097:blood; D007939:Leukemia L1210 / Q000188:drug therapy; D007942:Leukemia, Experimental / Q000188:drug therapy; D008545:Melanoma / Q000188:drug therapy; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy; D009588:Nitrogen Mustard Compounds / Q000138:chemical synthesis* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D006827:Hydantoins; D009588:Nitrogen Mustard Compounds; D007770:L-Lactate Dehydrogenase